Trump meets Zelenskiy, says Putin wants war to end, mulls trilateral talks
LEHI, Utah - Nature’s Sunshine Products, Inc. (NASDAQ:NATR), a $273 million market cap nutritional supplement manufacturer with $456.6 million in annual revenue, announced Wednesday a secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc.
The nutritional supplement manufacturer will not receive any proceeds from the offering as all net proceeds will go to the selling stockholder. Nature’s Sunshine may purchase up to $15 million of the offered shares as part of its previously announced share repurchase program, potentially funding this purchase through cash on-hand and credit facility draws. According to InvestingPro data, the company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 2.41.
D.A. Davidson & Co. is serving as the sole book-running manager for the offering, which is being made pursuant to a shelf registration statement on Form S-3 that became effective on June 18, 2025.
The company noted that while it has agreed it may purchase shares from the underwriters at the public offering price, it has not committed to purchasing a minimum amount and may decide to buy fewer or no shares.
Fosun Pharma USA will be responsible for paying underwriting discounts, commissions, and transfer taxes related to the resale of its shares, while Nature’s Sunshine will bear all other costs associated with registering the shares.
Nature’s Sunshine manufactures herbal and nutritional supplements and distributes its products in more than 40 countries. The company produces most of its offerings through its own facilities, achieving impressive gross margins of 71.7%. InvestingPro analysis shows multiple additional positive indicators for the company, with a comprehensive Pro Research Report available among the 1,400+ covered US stocks.
The information in this article is based on a press release statement from Nature’s Sunshine Products.
In other recent news, Nature’s Sunshine reported strong first-quarter 2025 earnings, surpassing market expectations with an earnings per share (EPS) of $0.25, compared to the projected $0.17. The company also exceeded revenue forecasts, posting $113.2 million against an anticipated $109.42 million. Furthermore, Nature’s Sunshine reaffirmed its full-year 2025 financial outlook, maintaining previous guidance for net sales and adjusted EBITDA. In related developments, DA Davidson reiterated a Buy rating on Nature’s Sunshine, maintaining a price target of $19.00, citing confidence in the company’s future prospects and management’s proactive strategies. The firm noted that Nature’s Sunshine is well-positioned to handle the upcoming CEO transition smoothly. The company also announced a $25 million share repurchase program, which is viewed as a strong indication of confidence in its future. Additionally, Nature’s Sunshine is undergoing a leadership change as CEO Terrence Moorehead will step down, with a search for his successor already underway.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.